Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A

Xiang Gu,Ai Zhuang,Jie Yu,Ludi Yang,Shengfang Ge,Jing Ruan,Renbing Jia,Xianqun Fan,Peiwei Chai

DOI: https://doi.org/10.1093/nar/gkad1193

IF: 14.9

2023-12-22

Nucleic Acids Research

Abstract:Albeit N1-Methyladenosine (m 1 A) RNA modification represents an important regulator of RNA metabolism, the role of m 1 A modification in carcinogenesis remains enigmatic. Herein, we found that histone lactylation enhances ALKBH3 expression and simultaneously attenuates the formation of tumor-suppressive promyelocytic leukemia protein (PML) condensates by removing the m 1 A methylation of SP100A, promoting the malignant transformation of cancers. First, ALKBH3 is specifically upregulated in high-risk ocular melanoma due to excessive histone lactylation levels, referring to m 1 A hypomethylation status. Moreover, the multiomics analysis subsequently identified that SP100A, a core component for PML bodies, serves as a downstream candidate target for ALKBH3. Therapeutically, the silencing of ALKBH3 exhibits efficient therapeutic efficacy in melanoma both in vitro and in vivo , which could be reversed by the depletion of SP100A. Mechanistically, we found that YTHDF1 is responsible for recognition of the m 1 A methylated SP100A transcript, which increases its RNA stability and translational efficacy. Conclusively, we initially demonstrated that m 1 A modification is necessary for tumor suppressor gene expression, expanding the current understandings of dynamic m 1 A function during tumor progression. In addition, our results indicate that lactylation-driven ALKBH3 is essential for the formation of PML nuclear condensates, which bridges our knowledge of m 1 A modification, metabolic reprogramming, and phase-separation events.

biochemistry & molecular biology